TGFB1 and renal fibrosis: These medications reduce the activity of TGFβ, plasminogen activator inhibitor-1 (PAI1), and platelet-derived growth factor (PDGF), all molecules involved in the pathogenesis of renal fibrosis [12,165,166,167].